| Zeit | Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Gilead Sciences Aktie: Wachstum trotz Dividendenrisiko | 385 | Boersia.de | Gilead Sciences Inc, ein führendes Unternehmen in der Entwicklung von Therapien für lebensbedrohliche Infektionskrankheiten, zeigte jüngst eine deutliche Performance an der Börse mit einem Anstieg von... ► Artikel lesen | |
| Fr | Gilead Sciences Jumps After Its Weight-Loss Drug Emerges From Under The Radar | 27 | Investor's Business Daily | ||
| Fr | What 8 Analyst Ratings Have To Say About Gilead Sciences | 15 | Benzinga.com | ||
| Mi | Gilead Sciences: How Luciana Preger Is Helping Advance Gilead's Work in Oncology | 216 | ACCESSWIRE | NORTHAMPTON, MA / ACCESSWIRE / June 12, 2024 / Gilead SciencesLuciana Preger credits being exposed to her father's work at a young age with helping inform her own career in medicine. Luciana is a physician... ► Artikel lesen | |
| 08.06. | Gilead Sciences Aktie: Aussichten auf Steigerung | 665 | Börse Global | Gilead Sciences hat den Investoren Optimismus verschafft, als die Aktie das jüngste Handelsende mit einer Steigerung von 1,33% auf $64,70 beendete und damit die Entwicklung des S&P 500 übertraf, welcher... ► Artikel lesen | |
| 06.06. | Gilead Sciences Aktie: Durchbruch in Hepatitis-Behandlung | 466 | Boersia.de | Gilead Sciences hat vielversprechende Daten aus Phase-2b- und Phase-3-Studienveröffentlicht, die bedeutende Fortschritte in der Behandlung von zwei schwerwiegendenLebererkrankungen aufzeigen. Bulevirtide... ► Artikel lesen | |
| 06.06. | Gilead Sciences, Inc.: Gilead Announces New England Journal of Medicine Publication of Data that Demonstrate Bulevirtide with PegIFN Achieved Post-Treatment Undetectable HDV RNA | 298 | Business Wire | - Phase 2b Data Presented at EASL and Published in NEJM Show Potential for Bulevirtide 10 mg in Combination with Pegylated Interferon Alfa-2a as Finite Therapy for People with Chronic Hepatitis... ► Artikel lesen | |
| 06.06. | Gilead Sciences Aktie: Fortschritt in Krebs- und Lebertherapie | 435 | Börse Global | Gilead Sciences zeigt bedeutende Entwicklungen in der Behandlung von seltener Leberkrankheit und unterstützt brustkrebsbetroffene Frauen bei Familienplanung. Die neuesten Daten konnten bemerkenswerte... ► Artikel lesen | |
| 05.06. | Gilead Sciences: Preserving Fertility in the Face of a Cancer Diagnosis | 227 | ACCESSWIRE | NORTHAMPTON, MA / ACCESSWIRE / June 5, 2024 / Emma was a 28-year-old nursing student when she was diagnosed with triple-negative breast cancer. She had always wanted children and, once she learned that... ► Artikel lesen | |
| 05.06. | Gilead Sciences, Inc.: Gilead's Seladelpar Demonstrated a Sustained and Consistent Long-Term Efficacy and Safety Profile in Primary Biliary Cholangitis | 371 | Business Wire | - Positive Results from Two-year Interim Analysis Includes Participants from Phase 3 RESPONSE Study and are Highly Consistent with One-year Interim Analysis - - Reduction in Patient-Reported... ► Artikel lesen | |
| 31.05. | Gilead Sciences ADC Flunks Its Confirmatory Test in Advanced Bladder Cancer | 18 | MedCity News | ||
| 28.05. | Gilead Sciences Partners With White House for Early Cancer Detection Program "Biden Cancer Moonshot" | 288 | ACCESSWIRE | NORTHAMPTON, MA / ACCESSWIRE / May 28, 2024 / Gilead Sciences:In an effort to advance access to cancer prevention and early detection among U.S. workers, the Biden Cancer Moonshot recently announced... ► Artikel lesen | |
| 22.05. | Gilead Sciences, Inc.: Gilead to Present Latest Research Across Key Liver Disease Indications at the European Association for the Study of the Liver Congress 2024 | 436 | Business Wire | Key Findings from PBC, HDV, HCV, HBV and MASH/Fibrosis Studies Affirm Commitment to Drive Life-changing Science in Liver Disease -
Gilead Sciences, Inc. (Nasdaq:GILD) today announced new research... ► Artikel lesen | |
| 21.05. | Gilead Sciences Hosts Inaugural Global Health Equity Summit | 357 | ACCESSWIRE | NORTHAMPTON, MA / ACCESSWIRE / May 21, 2024 / Driven by our purpose to make the world a healthier place for all people, we've worked to improve health equity and advance equitable access to care. Last... ► Artikel lesen | |
| 14.05. | Gilead Sciences, Inc.: Kite Data at EHA 2024 Demonstrate Positive Patient Outcomes and Advances in Delivery of CAR T-cell Therapy | 618 | Business Wire | - Analysis Comparing Real-World and Clinical Trial Data Show Yescarta Has Higher Manufacturing Success Rates and Improved T-Cell Performance, Respectively, in Second-Line vs. Third-Line+ Treatment... ► Artikel lesen | |
| 14.05. | Gilead Sciences: Native Health Navigator Program Connects Tribes to Cancer Care | 346 | ACCESSWIRE | NORTHAMPTON, MA / ACCESSWIRE / May 14, 2024 / Olivia Sloan was pursuing a career in health policy and research when her father was diagnosed with non-Hodgkin lymphoma. The devastating news put her work... ► Artikel lesen | |
| 10.05. | Decoding Gilead Sciences' Options Activity: What's the Big Picture? | 20 | Benzinga.com | ||
| 09.05. | GILEAD SCIENCES, INC. - 8-K, Current Report | 8 | SEC Filings | ||
| 09.05. | Gilead Sciences: Gilead's FOCUS Program Helps Zero In on Early HIV Detection | 661 | ACCESSWIRE | NORTHAMPTON, MA / ACCESSWIRE / May 9, 2024 / A 22-year-old college student who didn't feel well was treated at an urgent care facility in Baton Rouge, Louisiana and expected to recover soon. But when... ► Artikel lesen | |
| 09.05. | Will Gilead Sciences Stock Recover To Its Pre-Inflation Shock Highs Of Around $75? | 29 | Forbes |
Seite:
1 2 3 4 5 Weiter >>
| Suchbegriffe der letzen 24 h | Anzahl |
|---|---|
| NVIDIA | 416 |
| SNOWFLAKE | 297 |
| TUI | 256 |
| GAMESTOP | 250 |
| RHEINMETALL | 220 |
| EVOTEC | 179 |
| DEUTSCHE LUFTHANSA | 169 |
| NEL | 164 |
| BAYER | 155 |
| TESLA | 135 |
| BYD | 133 |
| VOLKSWAGEN | 104 |
| APPLE | 99 |
| BASF | 94 |
| PORSCHE SE | 90 |
| DEUTSCHE TELEKOM | 87 |
| THYSSENKRUPP | 83 |
| MERCEDES-BENZ | 82 |
| DEUTSCHE BANK | 76 |
| ALLIANZ | 68 |
| COMMERZBANK | 68 |
| BROADCOM | 64 |
| PLUG POWER | 64 |
| RWE | 64 |
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und
